Directory
>
Greg Motz
Greg Motz
VP, Immunology | BlueRock Therapeutics
Boston, Massachusetts, United States
Greg Motz
Summary
Greg Motz is a seasoned leader in the pharmaceutical and biotechnology sectors, currently serving as the VP of Immunology at BlueRock Therapeutics. With a robust background in cancer immunotherapy and drug development, he has successfully led teams through critical phases of research and clinical trials. His expertise spans a wide range of immunology topics, including CAR-T cell therapies and gene editing. Greg is recognized for his innovative approach to developing novel therapeutics that aim to significantly improve patient outcomes. His career reflects a commitment to advancing science through strategic collaboration and mentorship. With a history of impactful publications, he is a respected voice in the field of immunology.
Greg Motz
Work Experience
VP, Immunology at
BlueRock Therapeutics
July 2021 - Present
VP, Head of Biology at
Orna Therapeutics
January 2020 - January 2021
Sr. Director, Head of Research at
Cogent Biosciences
January 2016 - January 2020
Investigator II at
Novartis
January 2014 - January 2016
Greg Motz
Education
University of Pennsylvania
January 1970 - January 1970
Chhatrapati Shahu Ji Maharaj University, Doctorates
January 1970 - January 1970
Frequently Asked Questions about Greg Motz
What is Greg Motz email address?
Greg Motz's primary email address is *****@bluerocktx.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Greg Motz work for?
Greg Motz is a VP, Immunology at BlueRock Therapeutics, a company specializing in Commercial physical research.
Where Greg Motz graduated from?
Greg Motz holds a degree in from University of Pennsylvania.
How can I directly contact Greg Motz?
To contact Greg Motz directly, you can use the email address *****@bluerocktx.com. Complete contact information is available upon registration with Muraena.
Who is Greg Motz?
Greg Motz is a seasoned leader in the pharmaceutical and biotechnology sectors, currently serving as the VP of Immunology at BlueRock Therapeutics. With a robust background in cancer immunotherapy and drug development, he has successfully led teams through critical phases of research and clinical trials. His expertise spans a wide range of immunology topics, including CAR-T cell therapies and gene editing. Greg is recognized for his innovative approach to developing novel therapeutics that aim to significantly improve patient outcomes. His career reflects a commitment to advancing science through strategic collaboration and mentorship. With a history of impactful publications, he is a respected voice in the field of immunology.
Greg`s contact details
*****@bluerocktx.com
Colleagues
Vice President, Preclinical Development & Clinical Pharmacology
SVP Process & Analytical Development
Vice President, Assay Development
Vice President, Vendor Strategy & Partnerships
Vice President, GMP Manufacturing
Senior Vice President, Head of People & Culture
SVP, Global Head of Finance
Chief Scientific Officer
President and CEO
Board Member and SAB